Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1958

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 1958
---
 exceeding 18 months. In addition, in the event of a Change in Control, as defined in the Miller Employment
Agreement, on, or at any time during the 24 months following, the Change in Control, (i) we terminate Mr. Miller’s employment for
any reason other than Cause or Disability, as defined in the Miller Employment Agreement, or (ii) Mr. Miller terminates his employment
for Good Reason, Mr. Miller will be entitled to Change in Control severance. 

Mr. Miller is subject to non-competition and
non-solicitation during the term of his employment and for a period of 24 months after termination of his employment.

Landon Employment Agreement.
We entered into an Employment Agreement dated as of February 7, 2024 with Kristen Landon (the “Landon Employment
Agreement”), our Chief Commercial Officer. The term of the Landon Employment Agreement began on February 12, 2024 and will
continue at will, meaning that Ms. Landon or the Company may terminate the employment relationship at any time, with or without
cause, and with or without notice and for any reason or no particular reason. The Landon Employment Agreement provides Ms. Landon an
annual base salary of $300,000, sales bonuses and bonuses to the extent certain events occur or if applicable performance goals are
met and employee benefits that are generally given to our senior executives. Contingent on the receipt of shareholder approval to
increase the number of shares available under the 2022 Plan, Ms. Landon was granted a five-year option to purchase a total of 4,167
shares of our common stock with a per share exercise price to be determined by the Board on the date of grant. The options had a
cashless exercise price and vest annually over five years, with the first vesting date being December 31, 3024. On September 26,
2024, after the receipt of stockholder approval to increase the number of shares available under the 2022 Plan, the
Board approved the grant of the options to Ms. Landon at a per share exercise price of $6.85.  

69

OUTSTANDING
EQUITY AWARDS AT DECEMBER 31, 2024

    Option Awards  
      
    Stock Awards 
  
    Name 
    Number of securities underlying unexercised
    options, exercisable (#)  
    Number of securities underlying unexercised